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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1207CVD in the Developing WorldDavid S. Celermajer, Clara K. Chow, Eloi Marijon, Nicholas M. Anstey, Kam S. Woo
In 2001, it was estimated that there were 16 million deaths from cardiovascular disease
(CVD); 13 million of which occurred in low-income and middle-income countries. The
prevalence of traditional risk factors for atherosclerotic CVDs has been increasing in the
developing world. Furthermore, certain other diseases affecting the cardiovascular system
remain important causes of cardiovascular morbidity and mortality in developing countries,
including rheumatic heart disease and malaria. Celermajer and colleagues review the
epidemiology and the possibility of using imaging and functional studies to identify patients
for early treatment, which is more affordable.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
1217Improved Clinical and Angiographic Outcomes of Patients
Treated With EES Compared to PES for ULMDRenato Valenti, Angela Migliorini, Guido Parodi, Nazario Carrabba, Ruben Vergara, Emilio V. Dovellini,
David Antoniucci
Valenti and colleagues performed a retrospective, nonrandomized review to compare the
clinical and angiographic outcomes of patients treated with an everolimus-eluting stent (EES)
or first-generation paclitaxel-eluting stent (PES) for unprotected left main disease (ULMD).
Nearly 400 patients were included. The incidence of 1-year major adverse cardiovascular
events (MACE) was 22% in the PES group and 9.6% in the EES group. Target vessel
failure rate was 21% in the PES group and 7.8% in the EES group and the binary in-
segment restenosis rate was similarly reduced. EES implantation for ULMD is associated
with a reduced incidence of 1-year MACE, target vessel failure, and restenosis compared to
PES.(continued on page A-18)
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1223Lower Mortality When STEMI Patients Are
Transported Directly to a PCI-Capable HospitalMichel R. Le May, George A. Wells, Derek Y. So, Chris A. Glover, Michael Froeschl, Justin Maloney,
Richard Dionne, Jean-Franc¸ois Marquis, Edward R. O’Brien, Alexander Dick, Heather L. Sherrard,
John Trickett, Pierre Poirier, Melissa Blondeau, Jordan Bernick, Marino Labinaz
Le May and colleagues sought to determine if mortality complicating ST-segment elevation
myocardial infarction (STEMI) was impacted by the design of transport systems. Outcomes
were compared between patients transported directly to a percutaneous coronary intervention
(PCI)-capable hospital and those transported from the field to the hospital and then
subsequently for primary PCI. Death within 6 months occurred in 5.0% of patients
transferred directly from the field and in 11.5% transported from field to a non–PCI-capable
hospital. This mortality difference remained after multivariable logistic adjustment. These
results support the concept of STEMI systems, which include pre-hospital referral to a
PCI-capable hospital by emergency medical services.CARDIOMETABOLIC RISK1231Large Registry Shows Link Between Statins and Diabetes, Confirms Benefits of StatinsKang-Ling Wang, Chia-Jen Liu, Tze-Fan Chao, Chi-Ming Huang, Cheng-Hsueh Wu,
Su-Jung Chen, Tzeng-Ji Chen, Shing-Jong Lin, Chern-En Chiang
Wang and colleagues used data from the Taiwanese National Health System to study the
association between statin use and incident diabetes, and subsequent outcomes. Over a
median of 7.2 years, annual rates of diabetes were significantly higher in statin users (2.4% vs.
2.1%), whereas major adverse cardiovascular events (hazard ratio [HR]: 0.82 for myocardial
infarction, 0.94 for ischemic stroke) and in-hospital mortality (HR: 0.61) were lower. Further
analysis estimates that treatment with statins for 1 year prevented 1 fatal event for every
202 subjects treated and 1 diagnosis of diabetes for every 301 patients.HEART FAILURE1239Reduced Hospital Days With Home-Based Management of Chronic Heart FailureSimon Stewart, Melinda J. Carrington, Thomas H. Marwick, Patricia M. Davidson, Peter Macdonald,
John D. Horowitz, Henry Krum, Phillip J. Newton, Christopher Reid, Yih Kai Chan, Paul A. Scuffham
This prospective, multicenter, randomized trial compared the outcomes of patients with
chronic heart failure who were randomized to home-based intervention (HBI) or specialized
chronic heart failure clinic-based intervention. For HBI, patients were visited at home by a
nurse shortly after discharge. This nurse visit sought to evaluate any barriers to care and
included education for other family members or caregivers. There was no difference in the
primary endpoint of all-cause unplanned hospitalization or death during 12- to 18-month
follow-up, but the duration of hospitalizations was substantially shorter for the HBI group
resulting in lower costs.(continued on page A-19)
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EBIOMARKERS1249Gal-3, a Marker of Fibrosis, Predicts Incident Heart FailureJennifer E. Ho, Chunyu Liu, Asya Lyass, Paul Courchesne, Michael J. Pencina, Ramachandran S. Vasan,
Martin G. Larson, Daniel Levy
Galectin-3 (Gal-3) is expressed in activated macrophages, with binding sites localized to the
myocardial extracellular matrix and cardiac fibroblasts; it induces fibroblast proliferation,
collagen deposition, and ventricular dysfunction in animal models. Ho and colleagues used
samples collected from the Framingham Offspring Cohort to determine if Gal-3 serum levels
identify subjects at increased risk of incident heart failure. Gal-3 was associated with an
increased left ventricular mass in age- and sex-adjusted analyses. Gal-3 was also associated
with a risk of incident heart failure and remained significant after adjustment for clinical
variables and B-type natriuretic peptide. Future studies evaluating the role of Gal-3 in cardiac
remodeling appear warranted as this may be either a risk marker or a target for
pharmaceutical intervention.Editorial Comment: David A. Morrow, Michelle L. O’Donoghue, p. 1257HEART VALVE DISEASE
1259Low-Gradient Aortic Stenosis With Normal Ejection
Fraction Linked to Poor Outcomes, Benefit of Surgery SuggestedMarie-Annick Clavel, Jean G. Dumesnil, Romain Capoulade, Patrick Mathieu, Mario Sénéchal,
Philippe Pibarot
In patients with preserved ejection fraction, a discordance between the calculated aortic valve
area (AVA) and the gradient raises uncertainty regarding the actual severity of the stenosis.
Clavel and colleagues performed a case-match study comparing the outcomes of patients with
low-flow (left ventricular ejection fraction 50% but stroke volume index 35 ml/m2),
ow-gradient (mean gradient 40 mm Hg), and severe (AVA 1.0 cm2) aortic stenosis (AS)
o that of patients with high-gradient severe AS and patients with moderate AS. Patients
ith low gradient AS had lower 5-year survival. Aortic valve replacement was associated with
mproved survival in the low-gradient severe AS cohort. These findings suggest that
ow-gradient AS does not exclude the presence of a clinically severe stenosis.
ditorial Comment: Helmut Baumgartner, p. 1268(continued on page A-20)
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1271Cost-Effectiveness and Clinical Effectiveness of
Catheter-Based RD for Resistant HypertensionBenjamin P. Geisler, Brent M. Egan, Joshua T. Cohen, Abigail M. Garner, Ronald L. Akehurst,
Murray D. Esler, Jan B. Pietzsch
Geisler and colleagues developed a decision-analytic model to predict the long-term
cardiovascular benefits of catheter-based renal denervation (RDN) for patients with resistant
hypertension. In the Symplicity HTN-2 trial, RDN lowered systolic blood pressure (SBP) by
32 mm Hg from a mean of 178 mm Hg at baseline. The model operates by taking the
reductions in SBP observed in the trial and applying associations, known from the published
literature, between SBP and clinical events. In the model, RDN substantially reduced event
probabilities for cardiovascular outcomes and improved survival. The model suggests a 20%
chance of cost savings with RDN and a 95% chance that the additional cost is reasonable
given the improved quality adjusted life years.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH1278hCPCs Engineered With Pim-1 Kinase Enhance Myocardial RepairSadia Mohsin, Mohsin Khan, Haruhiro Toko, Brandi Bailey, Christopher T. Cottage, Kathleen Wallach,
Divya Nag, Andrew Lee, Sailay Siddiqi, Feng Lan, Kimberlee M. Fischer, Natalie Gude,
Pearl Quijada, Daniele Avitabile, Silvia Truffa, Brett Collins, Walter Dembitsky, Joseph C. Wu,
Mark A. Sussman
Mohsin and colleagues sought to improve on the reparative and regenerative potential of
human cardiac progenitor cells (hCPCs) by modifying them to overexpress Pim-1 kinase,
which has been shown to enhance cell survival. hCPCs were isolated from heart failure
patients undergoing left ventricular assist device implantation and were engineered to express
green fluorescent protein and either Pim-1 or vehicle. Functional tests of hCPCs were
performed with intramyocardial injection in a mouse infarction model. hCPCs with Pim-1
had significantly increased proliferation coupled with increased hemodynamic performance at
20 weeks. Further studies showed increased cellular engraftment and differentiation with
improved vasculature and reduced infarct size.Editorial Comment: Nanette Hahr Bishopric, p. 1288
